Search
Now showing items 1-1 of 1
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
(2017)
To the Editor:
The study by Fitzgerald et al. poses the question as to whether inclisiran is suitable for long-term treatment of hyperlipidemia. In contrast with PCSK9 antibodies, which target plasma PCSK9, inclisiran ...